Friendly bacteria for moderate-to-severe pancreatitis
Part of Digestive system clinical trials.
This study tests whether taking a specific friendly bacterium (Bifidobacterium longum) can help people with moderate-to-severe acute pancreatitis recover faster. Participants will either receive the bacterium or a placebo (inactive pill) for the first few days of treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have acute pancreatitis that started within the last 48 hours.
- You are between 18 and 75 years old.
- Your pancreatitis is moderate to severe (based on specific medical scores or blood tests).
- You have not used any probiotic supplements in the past month.
- You are not pregnant, breastfeeding, or allergic to Bifidobacterium longum.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how severe acute pancreatitis works by using advanced tests on your body's germs, chemicals, and proteins. It may help find better ways to treat patients with this condition.
This trial tests whether a fecal microbiota transplant (FMT) can help prevent infections in people with moderately severe or severe acute pancreatitis. You may qualify if you are between 18 and 75, have had pancreatitis for 15 to 21 days, and already have a feeding tube in place.
This study looks at how the bacteria in your gut (microbiome) might affect the severity of a first-time acute pancreatitis attack. It aims to see if certain gut bacteria can predict how serious the illness will be, which could help doctors treat patients better.
This trial tests whether a fecal transplant (transferring healthy gut bacteria from a donor) can help people with severe acute pancreatitis. It is for adults who are about 2 weeks past the onset of the disease and have started to recover but still have fluid buildup in the pancreas.
This trial tests a supplement called tributyrin (related to butyrate) to see if it can help prevent complications from acute pancreatitis when given early after diagnosis. It is for people having their first episode of pancreatitis, not for those with certain causes or weakened immune systems.
This trial tests if adding a probiotic (Bacillus subtilis and Enterococcus faecium) to standard lipid-lowering therapy helps people with mild pancreatitis caused by very high triglycerides. It aims to see if the combination reduces inflammation and speeds recovery.
Hear when a new Acute Pancreatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.